evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

60 questions · 61 findings · 7 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 12 · 19.7%GRADE not reported 2 · 3.3%Very low 13 · 21.3%Low 13 · 21.3%Moderate 12 · 19.7%High 9 · 14.8%

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo

Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis

Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Incidence of serious adverse events · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Contact immunotherapy (diphencyprone or… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with hair growth stimulants (minoxidil) (very low certainty).

1 finding from 1 review

Intervention not reported

Baricitinib (1 RCT; 75 participants) · patients with moderate to severe eczema

It is very uncertain whether the intervention changes baricitinib (1 RCT; 75 participants) (very low certainty).

1 finding from 1 review

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).

1 finding from 1 review

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review